- Hutchmed
- | 公告及新聞稿
London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at June 29, 2018, the issued share capital of Chi-Med consisted of 66,532,683 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.
The above figure of 66,532,683 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority’s Disclosure Rules and Transparency Rules.
For illustrative purposes only, the 66,532,683 ordinary shares would be equivalent to 66,532,683 CREST depositary interests (each equating to one ordinary share) which are traded on AIM or, if the CREST depositary interests were converted in their entirety, equivalent to 133,065,366 American depositary shares (each equating to one-half of one ordinary share) which are traded on Nasdaq.
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President,
Corporate Finance & Development
+852 2121 8200
U.K. & International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, Solebury Trout
+1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Susan Duffy, Solebury Trout
+1 (917) 499 8887 (Mobile)
sduffy@troutgroup.com
Investor Relations
Xuan Yang, Solebury Trout
+1 (415) 971 9412 (Mobile)
xyang@troutgroup.com
David Dible, Citigate Dewe Rogerson
+44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts
+44 (20) 7886 2500
London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:
| 1. | Name of applicant: | Hutchison China MediTech Limited | |
| 2. | Name of scheme: | (a) | Share Option Scheme conditionally adopted by Hutchison China MediTech Limited in 2005 (“2005 HCML Share Option Scheme”) |
| (b) | Share Option Scheme conditionally adopted by Hutchison China MediTech Limited in 2015 (“2015 HCML Share Option Scheme”) | ||
| 3. | Period of return: | From December 29, 2017 to June 28, 2018 | |
| 4. | Balance under scheme from previous return: | (a) | 2005 HCML Share Option Scheme: 304,999 ordinary shares of US$1 each |
| (b) | 2015 HCML Share Option Scheme: 1,000,000 ordinary shares of US$1 each | ||
| 5. | The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return: | (a) | 2005 HCML Share Option Scheme: Nil |
| (b) | 2015 HCML Share Option Scheme: 1,425,597 ordinary shares of US$1 each | ||
| 6. | Number of securities issued/allotted under scheme during period: | (a) | 2005 HCML Share Option Scheme: 85,646 ordinary shares of US$1 each |
| (b) | 2015 HCML Share Option Scheme: Nil ordinary shares of US$1 each | ||
| 7. | Balance under scheme not yet issued/allotted at end of the period: | (a) | 2005 HCML Share Option Scheme: 219,353 ordinary shares of US$1 each |
| (b) | 2015 HCML Share Option Scheme: 2,425,597 ordinary shares of US$1 each | ||
| 8. | Number and class of securities originally listed and the date of admission: | (i) | 2,560,606 ordinary shares of US$1 each admitted on June 26, 2007 |
| (ii) | 1,000,000 ordinary shares of US$1 each admitted on June 20, 2016 | ||
| (iii) | 1,425,597 ordinary shares of US$1 each admitted on April 27, 2018 | ||
| 9. | Total number of securities in issue at the end of the period: | 66,532,683 ordinary shares of US$1 each | |
| Name of contact: | Christian Hogg | ||
| Address of contact: | 21/F., Hutchison House, 10 Harcourt Road, Hong Kong | ||
| Telephone number of contact: | +852 2121 8200 | ||
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President,
Corporate Finance & Development
+852 2121 8200
U.K. & International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, Solebury Trout
+1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Susan Duffy, Solebury Trout
+1 (917) 499 8887 (Mobile)
sduffy@troutgroup.com
Investor Relations
Xuan Yang, Solebury Trout
+1 (415) 971 9412 (Mobile)
xyang@troutgroup.com
David Dible, Citigate Dewe Rogerson
+44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts
+44 (20) 7886 2500
London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2018 on Friday, July 27, 2018 at 7:00 am British Summer Time (BST).
An analyst presentation will be held at 9:00 am BST (4:00 pm Hong Kong Time) on the same day at Citigate Dewe Rogerson, 3 London Wall Buildings, London, EC2M 5SY, UK, which will be webcast via the company website at www.chi-med.com/investors/event-information. The presentation will be available to download before the analyst presentation begins.
For North America based analysts and investors, Chi-Med will also host a conference call with Q&A at 9:00 am Eastern Daylight Time (2:00 pm BST).
Details of the analyst presentation and conference call dial-in will be provided in the financial results announcement. A replay will also be available on the website shortly after each event.
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President,
Corporate Finance & Development
+852 2121 8200
U.K. & International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, Solebury Trout
+1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Susan Duffy, Solebury Trout
+1 (917) 499 8887 (Mobile)
sduffy@troutgroup.com
Investor Relations
Xuan Yang, Solebury Trout
+1 (415) 971 9412 (Mobile)
xyang@troutgroup.com
David Dible, Citigate Dewe Rogerson
+44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts
+44 (20) 7886 2500
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
The FRESCO Randomized Clinical Trial
Jin Li; Shukui Qin; Rui-Hua Xu; Lin Shen; Jianming Xu; Yuxian Bai; Lei Yang; Yanhong Deng; Zhen-dong Chen; Haijun Zhong; Hongming Pan; Weijian Guo; Yongqian Shu; Ying Yuan; Jianfeng Zhou; Nong Xu; Tianshu Liu; Dong Ma; Changping Wu; Ying Cheng; Donghui Chen; Wei Li; Sanyuan Sun; Zhuang Yu; Peiguo Cao; Haihui Chen; Jiejun Wang; Shubin Wang; Hongbing Wang; Songhua Fan; Ye Hua; Weiguo Su
Abstract
Importance
Patients with metastatic colorectal cancer (CRC) have limited effective and tolerable treatment options.
Objective
To evaluate the efficacy and safety of oral fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, as third-line or later therapy in patients with metastatic CRC.
Design, Setting, and Participants
FRESCO (Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients) was a randomized, double-blind, placebo-controlled, multicenter (28 hospitals in China), phase 3 clinical trial. From December 2014 to May 2016, screening took place among 519 patients aged 18 to 75 years who had metastatic CRC that progressed after at least 2 lines of chemotherapy but had not received VEGFR inhibitor therapy; 416 met the eligibility criteria and were stratified by prior anti-VEGF therapy and K-ras status. The final date of follow-up was January 17, 2017.
Interventions
Patients were randomized in a 2:1 ratio to receive either fruquintinib, 5 mg (n = 278) or placebo (n = 138) orally, once daily for 21 days, followed by 7 days off in 28-day cycles, until disease progression, intolerable toxicity, or study withdrawal.
Main Outcomes and Measures
The primary end point was overall survival. Key secondary efficacy endpoints were progression-free survival (time from randomization to disease progression or death), objectiveresponse rate (confirmed complete or partial response), and disease control rate (complete or partial response, or stabledisease recorded ≥8 weeks postrandomization). Duration of response was also assessed. Safety outcomes included treatment-emergent adverse events.
Results
Of the 416 randomized patients (mean age, 54.6 years; 161 [38.7%] women), 404 (97.1%) completed the trial. Median overall survival was significantly prolonged with fruquintinib compared with placebo (9.3 months [95% CI, 8.2-10.5] vs 6.6 months [95% CI, 5.9-8.1]); hazard ratio (HR) for death, 0.65 (95% CI, 0.51-0.83; P < .001). Median progression-free survival was also significantly increased with fruquintinib (3.7 months [95% CI, 3.7-4.6] vs 1.8 months [95% CI, 1.8-1.8] months); HR for progression or death, 0.26 (95% CI, 0.21 to 0.34; P < .001). Grades 3 and 4 treatment-emergent adverse events occurred in 61.2% (170) of patients who received fruquintinib and 19.7% (27) who received placebo. Serious adverse events were reported by 15.5% (43) of patients in the fruquintinib group and 5.8% (8) in the placebo group, with 14.4% (40) of fruquintinib-treated and 5.1% (7) of placebo-treated patients requiring hospitalization.
Conclusions and Relevance
Among Chinese patients with metastatic CRC who had tumor progression following at least 2 prior chemotherapy regimens, oral fruquintinib compared with placebo resulted in a statistically significant increase in overall survival. Further research is needed to assess efficacy outside of China.
Trial Registration ClinicalTrials.gov Identifier: NCT02314819
Citations and Links
Please follow the link below to access the publication:
JAMA. 2018;319(24):2486-2496.
London: Thursday, June 7, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on June 6, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting in 2015 (the “2015 HCML Share Option Scheme”).
Chi-Med granted 36,936 share options under its 2015 HCML Share Option Scheme to certain employees to subscribe for Ordinary Shares subject to the acceptance of the grantees. Details of such share options granted prescribed are as follows:
Date of grant: June 6, 2018
Exercise price of share options granted: GBP41.66 per Ordinary Share
Number of share options granted: 36,936 (each share option shall entitle the holder thereof to subscribe for one Ordinary Share)
Closing market price of Ordinary Shares on the date of grant: GBP41.40 per Ordinary Share
Validity period of the share options: From June 6, 2018 to June 5, 2028
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.
Forward Looking Statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med’s filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President,
Corporate Finance & Development
+852 2121 8200
U.K. & International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, Solebury Trout
+1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Susan Duffy, Solebury Trout
+1 (917) 499 8887 (Mobile)
sduffy@troutgroup.com
Investor Relations
Xuan Yang, Solebury Trout
+1 (415) 971 9412 (Mobile)
xyang@troutgroup.com
David Dible, Citigate Dewe Rogerson
+44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts
+44 (20) 7886 2500
-繼2017年ASCO年會上就FRESCO研究達到全部研究終點，呋喹替尼安全性良好，較其他靶向療法脫靶毒性更低等數據進行口頭報告後，和黃醫藥在2018年ASCO年會上公佈了FRESCO研究進一步的研究數據-
-亞組分析顯示呋喹替尼帶來的生存獲益在主要亞組中均非常穩健-
– 生存質量調整的生存分析顯示呋喹替尼可帶來生存質量獲益–
2018年6月4日：和黃中國醫藥科技（AIM/Nasdaq：HCM）子公司和黃醫藥今日宣佈在2018年美國臨床腫瘤學會（ASCO）年會上公佈了III期臨床試驗FRESCO進一步的研究數據。 2018年ASCO年會於6月1日至5日在美國伊利諾斯州芝加哥市舉辦。這次公佈的數據來自FRESCO研究納入的416名局部晚期或轉移性結直腸癌（CRC）患者。
呋喹替尼是一種高選擇性強效口服血管內皮生長因子受體（VEGFR）1,2及3的抑製劑。呋喹替尼的新藥上市申請（NDA）已被中國國家藥品監督管理局（CNDA）受理。其中，FRESCO研究數據也是NDA申報材料的一部分。此外，呋喹替尼在中國還在開展以肺癌（以三線肺癌為適應症的III期臨床研究FALUCA以及呋喹替尼聯合易瑞沙®以一線肺癌為適應症的II期臨床研究）和胃癌（以二線胃癌為適應症的III期臨床研究FRUTIGA）為適應症的多項臨床研究。此外，呋喹替尼在美國的臨床研究也正在進行中（I期橋接試驗）。
這次公佈的兩篇摘要內容如下：
一項在中國轉移性結直腸癌患者中對比呋喹替尼和安慰劑分別聯合最佳支持治療的隨機、雙盲、III期臨床研究FRESCO研究的亞組分析結果：既往是否接受過抗VEGF或抗EGFR靶向治療對研究結果的影響
報告人：徐瑞華
摘要其他作者：李進、白玉賢、鄧艷紅、楊磊、鐘海鈞、陳振東、潘宏銘、郭偉劍、束永前、袁瑛、徐建明、沈琳、王寧、王欣、遲海東、彭猛業、華燁、蘇慰國、秦叔逵
報告時間及地點：6月3日（週日）美國中部夏令時間（CDT）08:00-11:30；A廳；壁報版編號：#30
小節：胃腸道（結直腸）腫瘤
摘要號及連接：#3537；abstracts.asco.org/214/AbstView_214_215579.html
在FRESCO研究中，呋喹替尼為中國的三線轉移性CRC患者帶來了統計學上具有顯著意義且臨床意義也較明顯的獲益。這項研究通過分析FRESCO研究中既往接受過靶向治療（PTT）亞組和既往未接受過靶向治療（無PTT）亞組來探索既往靶向治療對呋喹替尼療效和安全性的影響。該亞組分析結果顯示，無論既往是否接受過靶向治療，呋喹替尼均能為三線轉移性CRC患者帶來臨床獲益，且未觀測到累積毒性。
在第20屆中國臨床腫瘤學會年會上公佈的研究結果顯示，呋喹替尼在各個亞組表現穩健，均能帶來獲益。在接受呋喹替尼治療的278位患者中，有111位既往接受過靶向治療。在PTT亞組中，呋喹替尼對比安慰劑可以顯著地延長患者的總生存期（OS）（中位OS：7.69個月vs 5.98個月；HR=0.63；p = 0.023）以及無進展生存期（PFS）（中位PFS：3.65個月vs 1.84個月；HR = 0.24；p<0.001）。呋喹替尼也能為既往接受過抗-VEGF治療的患者（N=84）帶來OS（中位OS：7.20個月vs 5.91個月；HR =0.68；p=0.066 ）和PFS（中位PFS：3.48個月vs 1.84個月；HR=0.24；p<0.001）的獲益。在無PTT亞組中，接受呋喹替尼治療的患者的中位OS為10.35個月，接受安慰劑的患者的中位OS為6.93個月（HR=0.63；p=0.01）；呋喹替尼治療患者的中位PFS為3.81個月，而安慰劑組患者的中位PFS為1.84個月（HR=0.28；p<0.001）。
此次在ASCO年會上公佈的數據顯示在PTT亞組中，接受呋喹替尼治療的患者未觀察到累積性的治療過程中出現的3級及以上不良事件。 PTT亞組和無PTT亞組患者在治療過程中出現的3級及以上不良事件發生率相似（61.3%和61.1%）。該亞組分析結果與之前公佈的FRESCO研究意向治療人群結果一致。
呋喹替尼治療轉移性結直腸癌的隨機III期臨床研究FRESCO研究中患者的生存質量調整的無症狀且無毒性時間（Q-TWiST）
報告人：白玉賢
摘要其他作者：李洪燕、王寧、郭曉軍、王偉、範頌華、徐建明、沈琳
報告時間及地點：6月3日（週日）美國中部夏令時間（CDT）08:00-11:30；A廳；壁報版編號：#37
小節：胃腸道（結直腸）腫瘤
摘要號及連接：#3544；abstracts.asco.org/214/AbstView_214_224293.html
這項特設（ad-hoc）研究通過分析FRESCO研究中呋喹替尼組和安慰劑組生存質量調整的無症狀且無毒性時間（Q-TWiST）來對比兩組患者生存質量調整的生存情況以及呋喹替尼在不同亞組中帶來的Q-TWiST獲益。 Q-TWiST分析旨在從患者的角度來評估不同治療手段相對的臨床獲益與風險，已在許多腫瘤治療方案的評估中得到了廣泛地應用。在Q-TWiST分析中，每個患者的生存時間都被劃分為三個部分：TOX（疾病進展前伴有3級及以上不良事件的時間）、TWiST（無疾病症狀且無3級及以上不良反應的時間）和REL（疾病進展或複發至死亡或隨訪結束的時間）。
接受呋喹替尼治療的患者相對於接受安慰劑的患者獲得了更長的Q-TWiST時間，且Q-TWiST獲益與患者既往接受過的化療線數和既往是否接受過抗-VEGF或抗-EGFR的靶向治療無關。 Q-TWiST的改善顯示呋喹替尼能夠為轉移性CRC患者帶來具有臨床價值的生存質量獲益。
更多ASCO年會相關信息請訪問am.asco.org查看。
關於呋喹替尼
呋喹替尼（HMPL-013）是一種新型的高選擇性小分子候選藥物。臨床研究證實：通過一日一次的口服劑量即可有效的抑制血管內皮生長因子受體（VEGFR），且脫靶毒性低於其他靶向療法。呋喹替尼良好的耐受性以及無藥物間相互作用的特性，為其與其他癌症療法相聯合提供了理論支持，例如當前正在進行的呋喹替尼聯合化療或其他靶向治療的臨床研究。 VEGFR在腫瘤的血管生成中起到了至關重要的作用，抑制VEGFR可以阻斷腫瘤新生血管形成，從而成為防止腫瘤增長和入侵的一種重要的治療策略。
關於呋喹替尼治療結直腸癌在中國的研發進展
2017年6月，CNDA（前“國家食品藥品監督管理局”）受理呋喹替尼以晚期結直腸癌（CRC）為適應症的新藥上市申請。 2017年9月，CNDA公佈因呋喹替尼具有明顯臨床價值而授予其優先審評的資格。呋喹替尼的新藥上市申請基於已經獲得成功的FRESCO研究的研究數據。該研究結果於2017年6月5日在ASCO年會上以口頭報告的形式公佈。該研究詳情可登錄clinicaltrials.gov，檢索NCT02314819查看。呋喹替尼的3項早期臨床研究為FRESCO研究的開展奠定了基礎，這3項早期臨床研究包括：納入40名實體瘤患者的I期臨床研究、納入62名結直腸癌患者的Ib期臨床研究以及納入71名結直腸癌患者的II期臨床研究。
其他呋喹替尼相關研發項目
肺癌：呋喹替尼以非小細胞肺癌（NSCLC）為適應症的III期註冊性臨床試驗FALUCA目前也正在中國展開。 FALUCA是一項隨機雙盲安慰劑對照的多中心臨床研究，目標受試者為二線系統化療失敗的晚期非鱗NSCLC患者。該研究患者入組工作已於2018年2月完成，共計納入527名患者（clinicaltrials.gov註冊號NCT02691299）。該研究基於一項設計相似、納入了91名三線NSCLC患者的II期臨床試驗。這項II期臨床試驗的結果已於2016年12月6日舉辦的第17屆世界肺癌大會上以口頭報告的形式公佈（clinicaltrials.gov 註冊號 NCT02590965）。
和FALUCA同時進行的還有另外一項II期臨床試驗。該試驗以呋喹替尼聯合易瑞沙®（吉非替尼）作為一線療法，治療晚期或轉移性NSCLC（clinicaltrials.gov 註冊號 NCT02976116）。該試驗的初步結果已於2017年10月16日舉辦的第18屆世界肺癌大會上以口頭報告的形式公佈。
胃癌：2017年10月，和黃醫藥啟動了呋喹替尼聯合紫杉醇（泰素®）以晚期胃癌或胃食管結合部（GEJ）腺癌為適應症的關鍵性III期臨床研究，這項研究被命名為FRUTIGA 。該研究是一項隨機雙盲安慰劑對照的多中心臨床研究，計劃納入500餘名患者，目標受試者為一線標準化療後進展的晚期胃癌或GEJ腺癌患者（clinicaltrials.gov 註冊號NCT03223376）。FRUTIGA是在一項Ib/II期臨床試驗的基礎上開展的，該試驗表明呋喹替尼聯合泰素®在這類患者中具有良好的耐受性和令人鼓舞的腫瘤緩解率（clinicaltrials. gov 註冊號NCT02415023）。
在中國范圍內，呋喹替尼由和黃醫藥和禮來合作開發。
美國橋接試驗：和黃醫藥於2017年12月在美國啟動一項多中心開放標籤的I期臨床試驗，旨在評估呋喹替尼在美國晚期實體瘤患者中的安全性、耐受性和藥代動力學特性（clinicaltrials.gov 註冊號NCT03251378）。
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer treated with fruquintinib in FRESCO
| Presenter: | Yu-Xian Bai |
| Other Authors: | Hongyan Li, Ning Wang, Xiaojun Guo, Wei Wang, Songhua Fan, Jian-Ming Xu, Lin Shen |
| Time & Location: | Sunday, June 3, 08:00 – 11:30 CDT; Hall A, Poster Board: #37 |
| Session: | Gastrointestinal (Colorectal) Cancer |
| Abstract No. & Link: | #3544; abstracts.asco.org/214/AbstView_214_224293.html |
Copies of this poster can be obtained from American Society of Clinical Oncology and the author of the poster.
| Presenter: | Ruihua Xu |
| Other Authors: | Jin Li, Yu-Xian Bai, Yanhong Deng, Lei Yang, Haijun Zhong, Zhendong Chen, Hongming Pan, Weijian Guo, Yongqian Shu, Ying Yuan, Jianming Xu, Lin Shen, Ning Wang, Xin Wang, Haidong Chi, Jack Peng, Ye Hua, Weiguo Su, Shukui Qin |
| Time & Location: | Sunday, June 3, 08:00 – 11:30 CDT; Hall A, Poster Board: #30 |
| Session: | Gastrointestinal (Colorectal) Cancer |
| Abstract No. & Link: | #3537; abstracts.asco.org/214/AbstView_214_215579.html |
Copies of this poster may be obtained from the American Society of Clinical Oncology.